We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pharvaris NV | NASDAQ:PHVS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.77 | -7.82% | 20.85 | 0.3968 | 33.80 | 22.575 | 20.59 | 22.36 | 27,497 | 01:00:00 |
From Nov 2023 to May 2024
By Denny Jacob
Clinical-stage company Pharvaris said the U.S. Food and Drug Administration lifted the clinical hold on the investigational new drug application for deucrictibant for the prophylactic treatment of hereditary angioedema attacks following a review of data from a study.
"The lift of the clinical hold in the U.S. enables us to progress the global development of deucrictibant for long-term prophylaxis," including a resumed Phase 2 study in the U.S., said Chief Executive Berndt Modig.
The FDA placed clinical studies of deucrictibant on hold in August 2022.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 22, 2024 07:20 ET (12:20 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Pharvaris NV Chart |
1 Month Pharvaris NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
